57 peptides reviewed.
Each entry is a canonical reference page — built to be the first answer when someone asks an LLM or a search engine about this peptide.
Semaglutide
Ozempic · Wegovy · Rybelsus
Long-acting GLP-1 analogue approved for type-2 diabetes and chronic weight management. The most rigorously studied peptide on this index.
Tirzepatide
Mounjaro · Zepbound
Dual incretin receptor agonist with larger weight reduction than semaglutide in head-to-head trials.
Liraglutide
Saxenda · Victoza
Daily GLP-1 analogue, first-in-class for chronic weight management. Older and shorter-acting than semaglutide.
Dulaglutide
Trulicity
Weekly GLP-1 analogue fused to an IgG4 Fc fragment for extended half-life. Approved for T2D and cardiovascular risk reduction.
Exenatide
Byetta · Bydureon
Synthetic version of exendin-4 (Gila monster). First-in-class GLP-1 agonist for T2D.
Retatrutide
LY3437943
Triple-receptor agonist in late-stage trials with ~24% mean weight loss at 48 weeks. Not yet approved.
Cagrilintide
AM833
Long-acting amylin analogue investigated alone and combined with semaglutide (CagriSema) for weight loss.
Orforglipron
LY3502970
Small-molecule oral GLP-1 agonist in phase 3; no food/water restrictions unlike Rybelsus.
Survodutide
BI 456906
Boehringer Ingelheim/Zealand dual agonist in late trials for obesity and MASH.
Ipamorelin
Selective GH secretagogue with minimal effect on cortisol or prolactin. Reported for sleep and recovery.
CJC-1295 (with DAC)
DAC:GRF
GHRH analogue with drug-affinity complex extending half-life to days. Sustained elevation of GH/IGF-1.
CJC-1295 (no DAC)
Modified GRF (1-29) · Mod GRF
Short-acting GHRH analogue used to pulse GH in combination with ghrelin mimetics.
Sermorelin
GRF 1-29 · Geref
Synthetic GHRH(1-29) historically marketed as Geref. Common in US anti-aging compounding.
Tesamorelin
Egrifta
Stabilised GHRH analogue approved for HIV-associated lipodystrophy; reduces visceral adipose tissue.
MK-677
Ibutamoren · Oratrope
Orally active non-peptide ghrelin mimetic. Sustained GH/IGF-1 elevation but increases appetite and water retention.
Hexarelin
Potent ghrelin mimetic, more cortisol and prolactin response than ipamorelin. Less used clinically.
GHRP-2
Ghrelin mimetic stronger than ipamorelin; moderate cortisol/prolactin rise.
GHRP-6
First-generation ghrelin mimetic with marked hunger-stimulating effect.
BPC-157
Body Protection Compound 157 · PL 14736
Synthetic 15-aa sequence derived from a gastric juice protein. Reported anecdotally for soft-tissue and tendon recovery.
TB-500
Thymosin Beta-4 fragment
Synthetic fragment of Thymosin β4. Reported for recovery; small clinical trials in cardiac and ophthalmic contexts.
Thymosin β4 (full)
TB4 · Timbetasin
Full-length 43-aa Tβ4. Distinct from the TB-500 fragment; clinical trials in dry-eye and cardiac repair.
KPV
α-MSH(11-13)
C-terminal α-MSH tripeptide with anti-inflammatory action; investigated for IBD and skin inflammation.
Larazotide
AT-1001
Investigational tight-junction regulator for coeliac disease; reduces zonulin-mediated permeability.
GHK-Cu
Copper Tripeptide-1
Naturally occurring copper-binding tripeptide. Topical use studied for skin remodelling; injectable use is anecdotal.
Argireline
Acetyl Hexapeptide-3 · Acetyl Hexapeptide-8
Cosmetic hexapeptide marketed as a topical anti-wrinkle agent. Modest effect in controlled studies.
Matrixyl
Palmitoyl Pentapeptide-4 · Pal-KTTKS
Palmitoylated collagen fragment marketed for topical anti-aging. Increases collagen synthesis in vitro.
SNAP-8
Acetyl Octapeptide-3
Extended Argireline variant; same mechanism in vitro, longer sequence.
Melanotan I
Afamelanotide · Scenesse
Linear α-MSH analogue (afamelanotide), approved as Scenesse for erythropoietic protoporphyria.
Melanotan II
MT-II
Cyclic α-MSH analogue, the parent of bremelanotide. Unapproved; significant adverse-event profile.
PT-141
Bremelanotide · Vyleesi
Cyclic α-MSH analogue approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Setmelanotide
Imcivree
MC4R-selective agonist approved for rare monogenic obesity (POMC, LEPR, BBS).
Selank
Russian synthetic heptapeptide marketed for anxiety; limited Western trials.
Semax
Russian synthetic heptapeptide derived from ACTH; nootropic and neuroprotective claims.
Cerebrolysin
Peptide mixture from pig brain; used in Europe and Asia for stroke and dementia. Not FDA-approved.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Investigational small peptide claimed to potentiate HGF/c-Met signalling. No human data.
FGL
FG Loop peptide
NCAM-derived mimetic studied in cognition and neuroinflammation models.
P21
CNTFR fragment
Experimental neurogenic peptide. Anecdotal cognitive use; no human trials.
DSIP
Delta Sleep-Inducing Peptide
Endogenous nonapeptide associated with delta-wave sleep. Effects on sleep architecture are inconsistent in human trials.
Epitalon
Epithalon · AEDG
Russian synthetic pineal-gland tetrapeptide. Marketed for longevity; evidence largely Russian/in-house.
Thymosin α1
Zadaxin · Tα1
Thymic-origin peptide marketed as Zadaxin in 30+ countries (not US) for chronic hepatitis B/C and as adjuvant.
Thymulin
FTS
Zinc-bound thymic peptide with immunomodulatory and analgesic properties in animal models.
SS-31
Elamipretide · Bendavia · MTP-131
Cardiolipin-binding tetrapeptide investigated for mitochondrial disease, heart failure, and dry AMD.
MOTS-c
Mitochondrially-encoded peptide implicated in insulin sensitisation and metabolic regulation.
Humanin
Mitochondrial-encoded peptide with cytoprotective effects in neurons.
Kisspeptin-10
KP-10
GnRH-releasing kisspeptin fragment; investigated for HPG-axis stimulation and fertility.
Gonadorelin
GnRH
Synthetic GnRH used clinically for diagnostic testing and HPG stimulation.
HCG
Human chorionic gonadotropin · Pregnyl · Ovidrel
Glycoprotein hormone used for ovulation induction and male hypogonadism. Strictly clinical.
Oxytocin
Pitocin · Syntocinon
Posterior pituitary nonapeptide. Clinical use for labour induction; off-label intranasal use for social/anxiety modulation.
AOD-9604
hGH 177-191
Modified hGH 177-191 fragment originally trialled for obesity; missed endpoints in phase 3.
Fragment 176-191
HGH Frag 176-191
Related GH C-terminal fragment widely sold as a weight-loss peptide. Clinical evidence weak.
5-Amino-1MQ
Small-molecule NNMT inhibitor sold alongside peptides; preclinical lipolysis and metabolic effects.
Tesofensine
NS2330
Investigational triple-reuptake inhibitor for obesity. Not a peptide — flagged for completeness because it is sold by RUO suppliers.
Adipotide
FTPP
Chimeric peptide targeting white-adipose vasculature. Phase 1 in obese humans; renal toxicity signal.
IGF-1 LR3
Long R3 IGF-1
Long-acting IGF-1 analogue with reduced IGFBP binding. Widely sold by RUO suppliers.
IGF-1 DES
DES(1-3) IGF-1
Short-acting IGF-1 analogue with high potency at sites of injection.
Mecasermin
Increlex
Recombinant hIGF-1 approved for severe primary IGF-1 deficiency.
Follistatin-344
FST-344
Soluble follistatin isoform sequestering myostatin and activin. Gene-therapy work in trials; injectable peptide use is anecdotal.